Aaron Hieb

Aaron Hieb

Auto-generated profile, based on publicly available information

Aaron Hieb

Genentech, Pharmaceutical Development, 1 DNA Way, South San Francisco, CA 94080

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Drug Delivery
Verified
Journal Article
Open access
SRShrirang V. Ranade
Shrirang V. Ranade
MWMark R. Wieland
Mark R. Wieland
TTTammy Tam
Tammy Tam
JRJennifer C. Rea
Jennifer C. Rea
JHJudit Horvath
Judit Horvath
JSJay Stewart
Jay Stewart
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond. The PDS includes an ocular implant, a customized formulation of ranibizumab, and four dedicated ancillary devices for initial fill, surgical implantation, refill-exchange, and explantation, if clinically indicated. Ranibizumab is an ideal candidate for the PDS on account of its unique physicochemical stability and high solubility. Controlled release is achieved via passive diffusion through the porous release control element, which is tuned to specific drug characteristics to accomplish a therapeutic level of ranibizumab in the vitreous. To characterize drug release from the implant, release rate was measured in vitro with starting concentrations of ranibizumab 10, 40, and 100 mg/mL, with release of ranibizumab 40 and 100 mg/mL found to remain quantifiable after 6 months. Using a starting concentration of 100 mg/mL, active release rate at approximately 6 months was consistent after the initial fill and first, second, and third refills, demonstrating reproducibility between implants and between multiple refill-exchanges of the same implant. A refill-exchange performed with a single 100-µL stroke using the refill needle was shown to replace over 95% of the implant contents with fresh drug. In vitro data support the use of the PDS with fixed refill-exchange intervals of at least 6 months in clinical trials.

13 June 2025 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
DSDaniel Skomski
Daniel Skomski
AJAndrea Ji
Andrea Ji
DKDrago Kuzman
Drago Kuzman
DCDidier Clenet
Didier Clenet
AHAaron Hieb
Aaron Hieb
DLDeclan Lowney
Declan Lowney
The perspective review discusses predictive stability computational modeling and scientific risk-based approaches to prospectively assess long-term stability and shelf-life of biotherapeutics and vaccines. New regulatory approaches are considered in the context of evolving industry guidelines which are expected to lead to increased usage in clinical trials and market applications. Case studies for many critical quality attributes are broadly covered. Model methodologies, complexities, and mitigations, as well as emerging technologies, are also explained. Outputs of an industry-wide survey elucidate how biopharmaceutical companies are navigating this changing environment. Altogether, it is suggested that predictive stability holds promise for accelerating patient access to new medicines by overcoming stability-related bottlenecks while further enhancing scientific understanding and product robustness.

1 November 2020 in Analytical Biochemistry
Verified
Journal Article
Closed access
PMPatricia Molina
Patricia Molina
ASArthur J. Schick
Arthur J. Schick
LWLeslie Welch
Leslie Welch
TNThomas Niedringhaus
Thomas Niedringhaus
GHGabriella del Hierro
Gabriella del Hierro
AHAaron Hieb
Aaron Hieb